On CNBC’s “Halftime Report Final Trades,” Jim Lebenthal of Cerity Partners said he is long-term bullish but a bit nervous for the short term on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).
RBC Capital analyst Brian Abrahams, on Feb. 20, maintained Vertex Pharmaceuticals with a Sector Perform rating and raised the price target from $407 to $408.
Shannon Saccocia of NB Private Wealth named iShares U.S. Financials ETF (NYSE:IYF) as her final trade.
Don’t forget to check out our premarket coverage here
Joshua Brown of Ritholtz Wealth Management picked Netflix, Inc. (NASDAQ:NFLX), saying the stock is close to its 52-week high.
Supporting his view, MoffettNathanson analyst Michael Nathanson, on March 17, upgraded Netflix from Neutral to Buy and raised the price target from $850 to $1100.
Price Action:
- Vertex Pharmaceuticals shares gained 0.5% to close at $502.55 on Thursday.
- iShares U.S. Financials ETF fell 0.6% during Thursday’s session.
- Netflix shares gained 0.6% to close at $976.72 on Thursday.
Check This Out:
Photo: Shutterstock